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Determining the burden of fungal 
infections in Zimbabwe
Lorraine T. Pfavayi1,2,3*, David W. Denning4, Stephen Baker5,6, Elopy N. Sibanda7,8,9 & 
Francisca Mutapi2,3
Zimbabwe currently faces several healthcare challenges, most notably HIV and associated infections 
including tuberculosis (TB), malaria and recently outbreaks of cholera, typhoid fever and COVID-19. 
Fungal infections, which are also a major public health threat, receive considerably less attention. 
Consequently, there is dearth of data regarding the burden of fungal diseases in the country. We 
estimated the burden of fungal diseases in Zimbabwe based on published literature and ‘at-risk’ 
populations (HIV/AIDS patients, survivors of pulmonary TB, cancer, chronic obstructive pulmonary 
disease, asthma and patients receiving critical care) using previously described methods. Where 
there was no data for Zimbabwe, regional, or international data was used. Our study revealed that 
approximately 14.9% of Zimbabweans suffer from fungal infections annually, with 80% having tinea 
capitis. The annual incidence of cryptococcal meningitis and Pneumocystis jirovecii pneumonia in 
HIV/AIDS were estimated at 41/100,000 and 63/100,000, respectively. The estimated prevalence 
of recurrent vulvovaginal candidiasis (RVVC) was 2,739/100,000. The estimated burden of fungal 
diseases in Zimbabwe is high in comparison to other African countries, highlighting the urgent need 
for increased awareness and surveillance to improve diagnosis and management.
Africa has an estimated population of 1.3 billion people and accounts for about 75% of all the 38 million human 
immunodeficiency virus (HIV)-infected people in the world. Notably, approximately 50% of all fungal-related 
deaths due to HIV infections are thought to occur in Africa; however accurate data are  lacking1,2. Data generated 
by the Global Action Funds for Fungal Infections (GAFFI), suggests an estimated 47.6 million Africans suffer 
from fungal diseases, of which 1.7 million suffer annually from a serious fungal  infection3. However, these esti-
mates are based on data from only a few African countries, and most likely underestimates the true prevalence.
Fungal diseases are life-threatening and are responsible for a largely silent epidemic, often hidden killers caus-
ing substantial morbidity and mortality in susceptible  individuals4. Patients with fungal infections occur across 
a huge spectrum of medical conditions often as co-infections or opportunistic  infections5 and are thus treated 
as separate entities, hindering progress in diagnosis and management of these  patients6. Only skin, hair, nails 
and mucosal infections can be clinically diagnosed (with much imprecision) without specific laboratory testing 
or medical assessment (radiology, mycology, histopathology) with expensive technologies requiring trained 
personnel. On the other hand, most life-threatening infections require the referred methods to be diagnosed, 
which is often out of the reach of patients in poor resource settings.
Nonetheless, substantial progress is being made to prevent and manage some of these fungal diseases. Myce-
toma and chromoblastomycosis have been included in the World Health Organisation (WHO) list of neglected 
tropical  diseases7,8 and new guidelines for the prevention and management of cryptococcal meningitis were 
recently  issued3.
Fungal infections such as histoplasmosis, mycetoma, chromoblastomycosis, sporotrichosis, cryptococcal 
meningitis and tinea  capitis9–13 have been reported in Zimbabwe, albeit in few and dated reports. Therefore, there 
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is need to update the information on the burden of these infections in Zimbabwe if they are to be prioritised 
for health intervention.
In the last three decades Zimbabwe’s health system has faced considerable  issues14, most notably the demand 
for providing healthcare services for the control of HIV and associated tuberculosis (TB) as well as for other 
endemic infections such as malaria and schistosomiasis. The recent  cholera15 and typhoid  fever16 outbreaks 
further exacerbated Zimbabwe’s health challenges. The impact of the current severe acute respiratory syndrome 
coronavirus (SARS-CoV-2)  pandemic17 on the health system has yet to be fully realised. Thus, given the current 
health prioritisations in the context of limited resources, controlling fungal infections is currently not a national 
 priority6. This may only change with the quantification of the burden of these diseases and their impact on human 
health in Zimbabwean population.
Thus, in this study, we sought to provide estimates of the burden of fungal infections by using local published 
data; for those diseases with no existing local data, we used data from neighbouring countries, or international 
sources.
Results
Using previously described methods, we were able to estimate the occurrence of 2,212,715 cases of fungal infec-
tions each year in Zimbabwe (Table 1). The rate of each fungal disease per 100,000 people in Zimbabwe is also 
represented in Fig. 1.
HIV-related fungal infections. Cryptococcus neoformans complex, Pneumocystis jirovecii (previously 
Pneumocystis carinii) and oropharyngeal candidiasis are the fungal diseases most commonly associated with 
AIDS. According to the UNAIDS 2019 report, 1.4 million Zimbabweans were living with HIV, 85% were on ART 
and 42,857 new AIDS cases at risk of opportunistic fungal  infections18. C. neoformans complex is the most com-
mon cause of meningitis globally and is a leading cause of mortality among HIV-infected  adults11,19,20 in these 
patients. We estimated 6,086 cases (40/100,000) of cryptococcal meningitis. PCP is a major cause of infection in 
those with HIV/AIDS, and unfortunately, most of these patients are undiagnosed or diagnosed late, particularly 
in resource-limited  settings21,22. In Zimbabwe, the largest reported series was 8 (22%) cases of PCP in 1989 of 
HIV-infected individuals with respiratory  symptoms23. Assuming 11% of newly diagnosed HIV/AIDS  adults24, 
develop PCP over 2 years, we estimated 9429 cases (63/100,000) of PCP. PCP may be proportionately more 
common in children with HIV and was likely a significant contributor to the 3000 children who died of AIDS in 
 201918, but we did not estimate this separately due to the absence of data. We estimated oral candidiasis to affect 
77,143 individuals and oesophageal candidiasis 63,571 people living with HIV (PLHIV).
Invasive aspergillosis (IA) and mucormycosis. We estimated a total of 2448 cases of IA annually 
(16/100,000) including 45 cases in haematological malignancy, 19 cases among those with lung cancer, 800 
Table 1.  Estimated burden of fungal diseases in Zimbabwe. I Incidence; P Prevalence; ABPA Allergic 
bronchopulmonary aspergillosis; SAFS Severe asthma with fungal sensitisation; CPA Chronic pulmonary 
aspergillosis; RVVC Recurrent Vulvovaginal Candidiasis a Rate among all females.





care + surgery Totals Burden Rate/100,000
Cryptococcal 
meningitis 6086 6086 I 41
Pneumocystis 
pneumonia 9429 9429 I 63
Invasive aspergil-
losis 800 19 46 1582 2448 I 16
CPA 6182 6182 P 42
ABPA 14,892 14,892 P 100
SAFS 19,657 19,657 P 132
Candidaemia 520 223 743 I 5.0
Candida perito-
nitis 111 111 I 0.8
Oral candidiasis 77,143 77,143 I 519
Oesophageal 
candidiasis 63,571 63,571 I 427
RVVC (≥ 4x/year) 203,585 203,585 P 2739a
Mucormycosis 30 30 I 0.2
Histoplasmosis 57 57 I 0.4
Fungal keratitis 2081 2081 I 14
Tinea capitis 1,806,700 1,806,700 P 12,156
Total burden 
estimated 2,012,366 157,086 40,750 596 1916 2,212,715 16,255.4
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cases among people who died HIV/AIDS and 1582 cases among persons admitted to hospital with COPD. The 
recognized association with transplantation procedures could not be estimated since these procedures were not 
undertaken in Zimbabwe during the relevant period. For mucormycosis we conservatively estimated only 30 
 cases25.
Histoplasmosis. Histoplasmosis is poorly described in Zimbabwe with limited epidemiological data. How-
ever, a study by Oladele et al.26 reports that Histoplasmosis capsulatum var capsulatum (HCC) and Histoplasmosis 
capsulatum var duboisii (HCD) coexist in Zimbabwe. We estimate 57 cases of histoplasmosis per year. This esti-
mate excluded non-disseminated forms of histoplasmosis.
Non-HIV-related fungal disease burden. Chronic pulmonary aspergillosis (CPA) is a complication of 
pulmonary TB that is often diagnosed late and may mimic pulmonary TB. It also affects patients with other 
pulmonary disorders, notably COPD, after pneumothorax and occasionally those with ABPA and  asthma27. We 
estimated 6840 of CPA cases per year. Fungal allergy exacerbates asthma, especially in adults. The prevalence of 
asthma in adults in Zimbabwe was estimated to be 6.9% using data from Democratic Republic of the  Congo28. 
We estimated 14,892 and 19,657 cases per year of ABPA and SAFS respectively. There may be some duplication 
between these entities as many ABPA patients have severe asthma. Therefore, the true ‘fungal asthma’ prevalence 
may be 75% of their total. Cystic fibrosis has not reported from Zimbabwe.
Candidaemia and Candida peritonitis were estimated to affect 743 and 111 patients, respectively. We did not 
estimate Candida peritonitis complicating chronic ambulatory peritoneal dialysis.
RVVC is defined as four or more episodes of vulvovaginal candidiasis per  year29. We estimated 203,585 
RVVC to occur among adult women in the general healthy female population in their fertile years, which may 
be conservative. Hormone replacement therapy can precipitate  RVVC30, but we did not estimate this.
Fungal keratitis often occurs following ocular trauma from vegetable  material31,32 and male agricultural work-
ers are at a greater  risk33. It often leads to blindness and a recent global estimate found a culture and microscopy 
positive annual incidence of 14/100,000, which translates into approximately 2080 cases in Zimbabwe. However, 













































































Annual incidence and prevalence of fungal diseases in zimbabwe
Fungal disease
Figure 1.  Annual incidence and prevalence of fungal infections in Zimbabwe. Bar charts representing the 
burden of fungal diseases per 100,000 people (a) incidence and (b) prevalence for each fungal disease with data 
available. CM, Cryptococcal meningitis; PCP, Pneumocystis pneumonia; candidiasis (oesophageal candidiasis) 
; Invasive candidiasis (candidaemia and Candida peritonitis); IA, Invasive aspergillosis; other mycoses 
(histoplasmosis and mucormycosis); CPA, Chronic pulmonary aspergillosis; ABPA, Allergic bronchopulmonary 
aspergillosis; SAFS, Severe asthma with fungal sensitisation; rVVC, recurrent vulvovaginal candidiasis.
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this number rises to approximately 2930 cases. Most of the infected eyes will go blind and some will perforate 
and require  removal34.
Cutaneous fungal infections are very common in southern Africa, but here we focus only on tinea capitis, 
given its transmissibility, scarring potential and occasional complications of  kerion35. We estimated 1,806,700 
schoolchildren suffering from tinea capitis. The two most frequent dermatophyte species isolated from tinea 
cases in Zimbabwean children were Trichophyton violaceum and Microsporum audouinii9. These species have 
been shown to be the most frequent dermatophyte species involved in tinea capitis among children in southern 
 Africa36–39. This observation is in accordance with a recent systematic review estimating the burden of tinea 
capitis among children in  Africa40. Figure 2 shows tinea capitis infection in two young school boys from rural 
Zimbabwe.
There were 14 chromoblastomycosis, 3 sporotrichosis and 5 mycetoma cases as reported by Ross and Gel-
fand in a 10-year survey of histological  material12,13. Only four cases of blastomycosis were reported in  199141, 
however some more recent isolates such as Blastomyces gilchristii have been  described42,43. Given that these older 
estimates are the only available data in Zimbabwe, we cannot use them for a reliable estimate of the current 
burden. The reports however show that these conditions occur in this population and may be underdiagnosed 
and under reported.
Discussion
A diverse range of fungal infections commonly occurs in Zimbabwe. Frequent HIV and TB co-infections con-
tribute to a higher prevalence of some fungal diseases. Each of these conditions on its own or in combination 
can predispose individuals to fungal  diseases44. To date, the burden of fungal infections in Zimbabwe has not 
been documented. Therefore, we conducted this study to estimate the burden of fungal infections/diseases in the 
country. Our study indicated that over 2 million people [2,212,715 (14.9%)] suffer from fungal disease annually, 
a higher number than most African countries. This figure is comparable to that of  Senegal45 and  Nigeria46 with 
tinea capitis being the most predominant fungal infection.
In Zimbabwe, we found that, following tinea capitis, the most frequent serious fungal diseases were recur-
rent vulvovaginal candidiasis, oral and oesophageal candidiasis. Vulvovaginal candidiasis (VVC) is a common 
gynaecological problem occurring among women globally, most commonly caused by Candida albicans47,48. 
In previous studies carried out in Zimbabwe among women presenting with symptomatic vaginal discharge, 
VVC prevalence rates ranged between 25 and 40%49,50 and we have estimated that 203,585 Zimbabwean women 
suffer from recurrent episodes. While recurrent vulvovaginal candidiasis (RVVC) is not life threatening, it is a 
significantly more severe clinical form than VVC. This is because of the recurrence of symptoms defined as four 
or more episodes per  year29,51 and it is a major health problem for sexually active women. RVVC affects quality 
of life and is associated with anxiety, depression and a loss of  productivity52–54. Our estimates, make the burden 
of RVVC in Zimbabwe the fifth highest among the Southern African Development Community (SADC) coun-
tries with available estimated  burdens44,55–57 and some data indicate that the prevalence of RVCC may be higher 
in Africa than other  continents54,58,59. Genetic factors have been suggested to be related to the susceptibility of 
Black/ African women to RVCC. However, comprehensive assessment of the role of genetics in RVCC is still 
lacking. Likewise, host-related and behavioural factors could also have a role to  play51,60,61.
Oral and oesophageal candidiasis occurs commonly in AIDS patients or those with other immunosuppressive 
conditions. Oral candidiasis is one of the most common fungal opportunistic infections in immunocompromised 
 individuals62,63 and was found to be the most common opportunistic infection in  Nigeria64 and Uganda before the 
initiation of highly active antiretroviral therapy (HAART)65. Fluconazole is the drug of choice in the treatment of 
oral  candidiasis62 because of its bioavailability and efficacy compared with other antifungal  drugs66,67. However, 
an increase in resistance of Candida species to fluconazole has been reported in some parts of  Africa68–71 and 
this is important to note because of the implications for morbidity and mortality  rates71,72.
Figure 2.  Tinea capitis infection in two young boys from rural Zimbabwe.
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Cryptococcal meningitis is the leading cause of meningitis in sub-Saharan  Africa44,73. Recent studies have 
shown that an increasing proportion of patients with cryptococcosis are ART-experienced74,75. In Uganda 3% of 
ART-experienced patients with virological failure were cryptococcal antigen (CrAg)  positive76 with a background 
rate of 5–10% cryptococcal meningitis. Consequently, to estimate the incidence of cryptococcal meningitis in 
Zimbabwe we doubled our at-risk population (ART naïve), being cognisant of the fact that virological failure does 
not always translate to immunodeficiency. We estimated the occurrence of 6086 cases of cryptococcal meningitis 
per year. We estimated 9429 cases of PCP in HIV/AIDS patients only. Although, PCP is common in  children77–79 
and also occurs in non-HIV infected patients we did not include these in our estimates due to paucity of data.
The prevalence of CPA was estimated at 42/100,000, which was relatively high compared to other African 
 countries55–57. South Africa had the highest prevalence, at 176/100,00044. The high number in Zimbabwe could 
reflect the relatively high burden of  tuberculosis80 and further studies are required to validate this. The diagno-
sis requires a combination of imaging and Aspergillus IgG antibody testing recently recognised as an Essential 
Diagnostic by  WHO81, however these are not routinely done in Zimbabwe. Notably a fifth (19%) of CPA patients 
who were TB smear negative and GeneXpert negative in Nigeria were incorrectly diagnosed as having pulmonary 
 TB82 with consequent inappropriate treatment.
Asthma is a significant public health problem in Zimbabwe and is often poorly  controlled83. Here we estimated 
that 595,677 adults have asthma. In Zimbabwe fungal sensitisation studies have not been conducted, nonetheless 
we were able to estimate the burden for ABPA and SAFS, which are collectively known as ‘fungal asthma’. Fungal 
asthma differs from allergic asthma. Although the bronchoconstriction can be alleviated by the bronchodilators 
and inhaled glucocorticosteroids used in the management of asthma, fungal diseases requires the administration 
of antifungal agents such as oral  itraconazole84–87 and voriconazole, which can only be prescribed if an accurate 
diagnosis has been made. These antifungal agents act by reducing the fungal load, thus minimizing the stimulus 
for the ongoing inflammatory  activity88. If inadequately managed fungal asthma can lead to significant complica-
tions such as long term steroid toxicity, bronchiectasis and  CPA89.
A review on the role of antifungals in the management of patients with severe asthma has recently been 
 published87. The paper highlights significant studies that confirm lower toxicity of treatment with azoles, par-
ticularly itraconazole for ABPA and provide recommendations for the use of antifungal agents in patients with 
severe asthma, airways fungal infection and fungal  colonisation87.
Dermatophyte infections, especially tinea capitis, are common among children all over Africa, particularly 
in areas with poor socioeconomic and sanitary  conditions90–92. They are a public health problem due to their 
contagious  nature55. Prevalence rates range from 10% to more than 70% in different regions of  Africa9,40,93,94. 
The estimate of tinea capitis in this study was based on Zimbabwean data from  19909. However, there may have 
been changes over time and these figures may not be a true presentation of the current situation in the country. 
Nonetheless, it remains a common clinical problem.
Mycetoma is a neglected tropical disease caused by fungi or bacteria and mainly affects the skin as well 
as the underlying  tissues95. The morbidity due to mycetoma is  high96 and there are currently no control pro-
grammes except in Sudan where it is highly  endemic7,8,97. Cases of mycetoma have been reported in many African 
 countries45,98–103 including  Zimbabwe12. Cases of chromoblastomycosis, sporotrichosis and blastomycosis have 
also been reported in Zimbabwe. However, to date there are no reports of disseminated Emergomyces infections 
in Zimbabwe albeit there are some reports from South  Africa104. Contributory factors include a low index of 
clinical suspicion, limited diagnostic capacity and a dearth of the requisite clinical and diagnostic expertise.
Most fungal infection studies in Zimbabwe are dated having been carried out about two decades  ago9–11,23. 
While these indicate susceptibility in this population, they do not accurately represent the current situation in 
the country, especially with changes in the epidemiology of HIV whose prevalence has gone down from more 
than 15%14 to about 8.7% with 85% of these receiving ART 18. The health and economic challenges faced by the 
country with respect to public health priorities, clinical and laboratory expertise, the inadequacy of financial 
resources militate against the early diagnosis and treatment of fungal infections. Consequently, these health 
system limitations contribute to high rates of morbidity and  mortality105.
As most serious fungal infections are opportunistic infections, a majority of the affected individuals are 
 immunocompromised4. For example, cryptococcal meningitis, oesophageal candidiasis, PCP as well as aspergil-
losis are among the most common systemic fungal infections observed in HIV and AIDS patients, thus a combi-
nation of the underlying immunocompromised and superimposed fungal infection contributes to a higher risk 
of  mortality106. The comorbidities necessitate the co-administration of drugs, resulting in drug-drug interactions 
(DDIs). In some cases, optimum therapy for fungal infections is contraindicated in conjunction with medicines 
used to treat co-morbid conditions in an attempt to prevent potential adverse effects and treatment  failure107,108.
The preferred treatment for these fungal infections includes the administration of amphotericin B or azole 
antifungals such as fluconazole, itraconazole and voriconazole. All of these except voriconazole are on Zimba-
bwe’s essential list of  medicines109 and studies from other countries have suggested that renal function should be 
closely monitored with concomitant use of amphotericin B and tenofovir as both drugs can cause nephrotoxicity. 
Similarly, combination therapy of zidovudine and amphotericin B may result in anaemia and  neutropenia108. 
Hence, as DDIs are often unavoidable in HIV-infected patients, the potential effects of these DDIs cannot be 
 ignored106 especially in Africa where very few drugs used have been evaluated for DDIs and  pharmacogenetics110. 
This will potentially help in the management of patients suffering from co-morbidities as well as broaden our 
understanding of the effect of these DDIs in different populations. In addition to DDIs there is also a possibility 
of antifungal  resistance111. Previous studies have reported fluconazole resistance among C. neoformans complex 
isolates from  Africa112 and among Candida spp. isolated from women with  VVC113. This has a large impact on 
health and well-being of affected individuals.
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Study limitations. Despite an exhaustive search in this study, we could not obtain enough local data to 
use for a precise estimate of the current burden, as most of the available studies were outdated. So, majority of 
the data used was obtained from other countries, which may introduce some inaccuracies when estimating the 
burden in Zimbabwe due to socioeconomic and geographical  differences114. Another significant limitation is the 
incomplete nature of the estimates: for example, we could not estimate the burden of PCP in children or non-
HIV patients, the burden of mycetoma, chromoblastomycosis as well sporotrichosis could not be estimated due 
to paucity of data despite reports of cases in the country. Nonetheless, our results show that fungal diseases are 
probably much more common than are documented in clinical practice. Our estimates provide a starting point 
from which to better understand the extent of the problem in the country and create awareness and propose 
appropriate studies and interventions to address fungal diseases that are of significant public health importance.
Recommendations. Educating the community about fungal diseases is an important step in raising aware-
ness about the morbidity and mortality associated with these diseases. For most villages and communities across 
Zimbabwe, the entry point to health and health information dissemination is vested in the Community/Village 
Health Workers. These people are therefore integral in promoting awareness and assisting in early detection of 
symptoms associated with fungal diseases. Their knowledge of a community’s languages and customs means that 
they are able to deliver health messages to groups in a culturally appropriate manner, which is also easily under-
stood. This is an effective means of disseminating information to community members resulting in community-
based surveillance, which improves the likelihood of early case  detection115, as well as reducing the stigma asso-
ciated with some of the fungal diseases. The medical mycology community in Zimbabwe should therefore work 
closely with local organisations and community health workers to raise awareness of fungal diseases.
Schools are also a good place to promote campaigns aimed at raising awareness about fungal infections. For 
example, the neglected tropical disease, schistosomiasis, is a public health burden in  Zimbabwe116. Educational 
campaigns in schools including essay competitions, drama and ‘edutainment’ are ways in which awareness about 
the disease is raised in communities. A similar approach could be used to create awareness about fungi diseases 
among school children.
To increase the access to better diagnostics locally, a standardised diagnostic algorithm based on clinical 
signs and symptoms that can be easily identified by primary healthcare  professionals117 can be developed. The 
algorithm will help in early diagnosis and treatment of fungal diseases as well as ensure wealth of information on 
fungal diseases affecting the African population. This will allow interventions to be implemented in the primary 
healthcare setting and has the potential to significantly reduce morbidity and improve quality of life.
Conclusion
This study is the first to estimate the burden of fungal diseases in Zimbabwe and to provide an estimation of its 
impact on public health. The paucity of data on fungal infections in the country warrants for further epidemiol-
ogy studies and better diagnostics to aid patient management.
Methods
The prevalence and incidence of fungal disease in Zimbabwe were calculated following methods previously 
 described118,119 and the applied formulae will be detailed below. The burden was estimated for the general healthy 
population and for the ‘at- risk’ populations including HIV/AIDS patients, survivors of pulmonary TB, cancer, 
chronic obstructive pulmonary disease (COPD), asthma and patients receiving critical care. National or local 
data were preferred, but where these were unavailable, data were extrapolated from other sources. The annual 
burden was estimated for each fungal disease and presented as: (i) absolute number of cases per year in the 
country and (ii) annual rates. The absolute cases were presented as either incidence or prevalence depending 
on the nature of infection. The annual rates (incidence or prevalence) were calculated using the absolute annual 
number of cases as the numerator and the entire Zimbabwean population as the denominator. For simplicity, the 
2019 Zimbabwean population (n = 14,863,000120) was used regardless of the year from which the numerator data 
originated. The United Nations population estimates 2019, WHO reports, and The Joint Nations Programme on 
HIV/AIDS (UNAIDS) were used for the population demographics.
Calculating fungal disease burden. Prevalence or incidence was calculated using data from published 
studies. Prevalence was calculated for allergic bronchopulmonary aspergillosis (ABPA), severe asthma with fun-
gal sensitisation (SAFS), chronic pulmonary aspergillosis (CPA), recurrent vulvovaginal candidiasis (RVCC), 
and tinea capitis and the remaining estimates were calculated as annual incidence. Due to paucity of data, we 
were not able to calculate both prevalence and incidence for each disease.
Prevalence. To calculate the prevalence of ABPA, SAFS, CPA, RVCC, and tinea capitis we applied the same 
formulae used by GAFFI members to estimate the prevalence of fungal diseases in other  countries55,60,121,122.
Annual incidence. To calculate the incidence of invasive aspergillosis, oesophageal candidiasis, candidemia 
and Candida peritonitis we applied the same formulae used to estimate the incidence in other  countries55,60,121,122. 
For cryptococcal meningitis, Pneumocystis pneumonia and oral candidiasis, instead of calculating a figure based 
on the denominator, we doubled our at-risk population (ART naïve), being cognisant of the fact that virological 
failure does not always translate to immunodeficiency.
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The values above and the assumptions made to obtain the accurate denominators were obtained from a 
systematic literature search detailed below. The assessment of the quality of the source data, country profile and 
assumptions made for the analyses are detailed below.
Data sources and search terms. Published papers were identified from four databases: PubMed, Web of 
Science, EMBASE and Google Scholar. The following search terms were used: fungal infection, fungal burden, 
fungal epidemiology, Zimbabwe, Southern Africa, and Africa. A second search included the same searches using 
the following diseases: Cryptococcus/cryptococcal, Candida/thrush, Aspergillus/aspergillosis, histoplasmosis, 
asthma, leukaemia, chronic obstructive pulmonary disease (COPD), Pneumocystis pneumonia/Pneumocystis 
jirovecii pneumonia (PJP)/Pneumocystis carinii pneumonia, chronic pulmonary aspergillosis (CPA), aspergil-
loma, allergic bronchopulmonary aspergillosis (ABPA), severe asthma with fungal sensitisation (SAFS), tinea/
ringworm. We used HIV data to estimate the burdens of cryptococcal meningitis (CM), candidiasis and Pneu-
mocystis jirovecii pneumonia (PCP). Asthma, chronic obstructive pulmonary disease and tuberculosis data were 
used to estimate the presumed burden of allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmo-
nary aspergillosis (CPA). Burdens of candidaemia and Candida peritonitis were derived from critical care and/ 
or cancer patients’ data.
Papers presenting incidence or prevalence of any fungal disease were evaluated using an adapted Grading 
of Recommendations, Assessment, Development and Evaluations (GRADE)  score123 based on the following 
features: diagnostic accuracy, study size (using a cut-off of > 10 cases), year of study, with more recent studies 
scoring higher, type of publication, with original research article scoring more, methodology and country, with 
studies from Zimbabwe scoring higher (Table 2). Those with an adapted GRADE mean score of > 2 were deemed 
acceptable and enabled a minimum estimation of the country burden of fungal diseases (Table 3). Papers with 











Annual new AIDS cases× Proportion of AIDS patients presenting with Pneumocystis pneumonia
)
× 2
Oral candidiasis = (Annual new AIDS cases × 0.9) × 2
Table 2.  Scoring system for modified GRADE criteria.
Diagnostic Score
PCR + laboratory + clinical + imaging 2
Culture, smear, histology 1
Clinical suspicion only 0
Patient sample size Score
≥ 10 1
< 10 0




Country (data used) Score
Zimbabwe 2
Any other African country 1
Rest of the world 0
Methodology (well designed) Score
Yes 1
No 0
Type of publication Score
Research paper 2
Case study/short reports 1
Review papers 0
Possible total score 10
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Country profile. Zimbabwe is a landlocked country situated in Southern Africa, between the Zambezi and 
Limpopo Rivers, bordered by Botswana, Mozambique, South Africa and Zambia. In 2019, the Zimbabwean 
population was projected to be 14.9 million, with 58%  adults120. The number of people living with HIV/AIDS 
(PLWH) as of 2019 was estimated to be 1.3 million. The population estimates and HIV-related deaths were 
obtained from World Population Prospects and UNAIDS respectively and are shown in Table 4 18,120. National 
TB data were obtained from the World Health Organization (WHO)80. National prevalence data for lung cancer, 
chronic obstructive pulmonary disease (COPD), diabetes and incidence data for acute myeloid leukemia (AML) 
were obtained from the 2016 Global Burden of Disease  study134. To estimate the burden for HIV-related fungal 
diseases, we have assumed a 7-year linear decline in CD4 count to < 200 ×  106/l, of those not on ART, doubled to 
reflect those on ART who fail with ARV resistance or default (at risk of opportunistic infections).
Table 3.  Modified GRADE score for the papers used for estimating burden of fungal diseases in Zimbabwe. 
CM Cryptococcal meningitis, PCP Pneumocystis pneumonia, CPA chronic pulmonary aspergillosis, ABPA 
allergic bronchopulmonary aspergillosis, SAFS severe asthma with fungal sensitisation, IA invasive candidiasis, 





size n > 10 Up to date
Type of 
publication Methodology Country Overall score References
PCP 2 1 1 2 1 1 8 24
Histoplasmosis 1 1 1 1 0 2 6 10
Invasive asper-
gillosis
2 1 1 2 1 0 6 124
1 1 0 1 1 0 4 125
1 1 1 1 1 0 5 126
0 1 1 1 1 0 4 127
Candidaemia – – 1 0 1 – 2 128
Candida 
peritonitis 1 1 1 1 1 0 5
129
ABPA – – 1 0 1 – 2 130
SAFS – – 1 0 1 – 2 89
CM – – 2 0 1 – 3 131
RVVC – – 2 0 1 0 3 132
Tinea capitis 1 1 0 2 1 2 7 9
Mucormycosis 0 1 1 1 1 0 4 133
Fungal keratitis – – 1 0 1 – 2 34
Table 4.  Country’s profile. Populations and rates required to calculate burden fungal-related diseases in 
Zimbabwe. COPD chronic obstructive pulmonary disease, GOLD Global initiative for Obstructive Lung 
Disease, ARV antiretroviral, OI opportunistic infection, AML acute myeloid leukaemia.




Children (< 15 years), 6,230,000
Total number of adults, 8,633,000
Adult women 4,489,160
HIV/AIDS
Current total HIV/AIDS 1,400,000
18
Children with HIV 84,000
Proportion of diagnosed cases on ARVs 85%
Number of diagnosed cases receiving ARVs 1,100,000
Proportion of those on ARVs who fail or have ARV resistance




Annual new AIDS cases (at risk of OIs) 42,857
AIDS-related deaths 20,000
Respiratory diseases




Prevalence of asthma in adults 6.9%




Lung cancer 744 134
Diabetes 4.6% 139
Leukaemia AML 230 140
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Assumptions from other published reports were used to identify the most accurate denominators to use for 
our estimates and these are summarised in Table 5. In brief, PCP frequency was estimated by assuming 11% of 
newly diagnosed HIV/AIDS adults with the risk spread over 2  years24. The prevalence of AIDS patients presenting 
with cryptococcal meningitis was assumed to be 7.1% based on a study by Rajasingham et al.131 among antiret-
roviral therapy (ART)-naive HIV patients. Chronic pulmonary aspergillosis (CPA) prevalence was estimated 
using the previously described approach taken by Denning et al.141, where the number of annual PTB cases with 
cavities (22%) was multiplied by the incidence of CPA in cavities (22%) and the number of PTB cases without 
cavities (78%) was multiplied by CPA incidence (2%). An estimation of a 5-year prevalence of CPA was made, 
assuming a 15% annual mortality or surgical cure  rate130. To calculate all cases of CPA, PTB was assumed to 
be the underlying disorder in 67% of  cases142. Invasive aspergillosis was estimated in haematological and lung 
malignancies, HIV/AIDS and COPD. It was assumed that 10% of acute myeloid leukemia (AML) patients develop 
IA and that an equal number of cases are found in non-AML haematological patients while 1.3% of admitted 
COPD  patients124, 2.6% of lung cancer  patients127 and 4% HIV/AIDS patients who died develop  IA125. ABPA 
estimation was made assuming that 2.5% of adult asthmatics have  ABPA130,143 and although ABPA also occurs 
in cystic fibrosis, no estimate of the prevalence of this disease in Zimbabwe was attainable. The estimate of SAFS 
was as estimated at 33% of the most severe asthmatics (10%)89.
Oral candidiasis was assumed to affect 90% of untreated HIV patients over 12 months, based on a study in 
 Tanzania144. Oesophageal candidiasis was assumed to affect 20% of advanced HIV disease patients and 0.5% of 
HIV patients on ARV  treatment145,146. Mucormycosis was estimated to occur at a rate of 0.2/100,000 (literature 
estimate)25. Candidaemia cases were estimated assuming it occurs at a rate of 5 per 100,000 with 30% in ICU 
(critical care and post-surgical patients) and 70% in cancer and other immunocompromised and hospitalised 
 patients128. For Candida peritonitis (intrabdominal candidiasis), we assumed that the rate was half of the ICU 
candidemia  rate129. The estimated prevalence of RVVC was established assuming a frequency rate of 6% in adult 
 women132. Tinea capitis was estimated at 29% prevalence amongst schoolchildren in  Zimbabwe9.
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